Premium
Treatment of Acute Neuroleptic‐Induced Movement Disorders
Author(s) -
Tonda Margaret E.,
Guthrie Sally K.
Publication year - 1994
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1994.tb02851.x
Subject(s) - akathisia , amantadine , anticholinergic , medicine , parkinsonism , anticholinergic agents , dystonia , clonidine , anesthesia , adverse effect , benzodiazepine , extrapyramidal symptoms , concomitant , pharmacology , psychiatry , schizophrenia (object oriented programming) , antipsychotic , receptor , disease
Acute extrapyramidal syndromes (EPS), including dystonia, parkinsonism, and akathisia, are associated with the use of virtually all neuroleptic agents. They may be alleviated by reducing the neuroleptic dosage, switching to a lower‐potency drug, or administering an adjunctive agent such as an anticholinergic, amantadine, benzodiazepine, or β‐blocker. Akathisia may be only partly dispelled by anticholinergics; alternatives are β‐blockers, benzodiazepines, and clonidine. In patients receiving long‐term neuroleptic therapy, both the prophylactic use and the duration of treatment with concomitant anti‐EPS drugs are controversial. Administration of prophylactic anti‐EPS drugs should be based on the likelihood that the patient will develop EPS, as well as the risk of adverse reactions resulting from extended use of the agents in a specific patient. The decision to continue anti‐EPS therapy should be reevaluated frequently, especially in elderly patients.